NTRK3 G623R

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma2
NTRK3 G623R AND EML4::NTRK3 Fusion	Entrectinib	Predictive	C	Supports Resistance	2	accepted	EID11515 A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer had initially responded with a partial response to the NTRK inhibitor entrectinib for 12 months. Upon pro… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
NTRK3 G623R AND EML4::NTRK3 Fusion	Repotrectinib	Predictive	C	Supports Sensitivity Response	2	accepted	EID11516 A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer progressed after 12 months treatment with the NTRK inhibitor entrectinib with the emergence of an NTRK3 G… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Non-Small Cell Carcinoma2

NTRK3 G623R AND EML4::NTRK3 Fusion

Entrectinib

Predictive

Supports Resistance

accepted

EID11515

A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer had initially responded with a partial response to the NTRK inhibitor entrectinib for 12 months. Upon pro… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

civic

NTRK3 G623R AND EML4::NTRK3 Fusion

Repotrectinib

Predictive

Supports Sensitivity Response

accepted

EID11516

A 43-year-old-male with an EML4::NTRK3 rearrangement in metastatic non-small cell lung cancer progressed after 12 months treatment with the NTRK inhibitor entrectinib with the emergence of an NTRK3 G… (full text at CIViC)

PMID 34625502 · Murray et al., 2021 · Open in CIViC

Malignant Neoplasm1
ETV6::NTRK3 Fusion AND NTRK3 G623R	ALK/TRK Inhibitor TSR-011 + Crizotinib + Entrectinib + LarotrectinibSubstitutes	Predictive	D	Supports Resistance	3	accepted	EID10093 BaF3 cells were transduced with an ETV6-NTRK3 fusion construct with or without the additional NTRK3 G623R resistance mutation. These cells were then treated with common Trk inhibitors to measure the r… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic

Malignant Neoplasm1

ETV6::NTRK3 Fusion AND NTRK3 G623R

ALK/TRK Inhibitor TSR-011 + Crizotinib + Entrectinib + LarotrectinibSubstitutes

Predictive

Supports Resistance

accepted

EID10093

BaF3 cells were transduced with an ETV6-NTRK3 fusion construct with or without the additional NTRK3 G623R resistance mutation. These cells were then treated with common Trk inhibitors to measure the r… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

civic

Solid Neoplasm3
NTRK3 G623R	Larotrectinib	Predictive	C	Supports Resistance	2	submitted	EID7268 Patients with solid tumor that have a NTRK fusion were treated with larotrectinib. NTRK mutations were detected in patients with acquired resistance. Open in CIViC	civic
NTRK3 G623R	Selitrectinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID7270 Patients with solid tumor havoring NTRK fusion were treated with Larotrectinib. NTRK3 G623R mutation was deteceted in the tumor with acquired resistance. This patient was successfully treated with LOX… (full text at CIViC) Open in CIViC	civic
v::NTRK3 Fusion AND NTRK3 G623R	Larotrectinib	Predictive	A	Supports Resistance	3	submitted	EID11541 In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC) PMID 29466156 · Drilon et al., 2018 · Open in CIViC	civic

Solid Neoplasm3

NTRK3 G623R

Larotrectinib

Predictive

Supports Resistance

submitted

EID7268

Patients with solid tumor that have a NTRK fusion were treated with larotrectinib. NTRK mutations were detected in patients with acquired resistance.

Open in CIViC

civic

NTRK3 G623R

Selitrectinib

Predictive

Supports Sensitivity Response

submitted

EID7270

Patients with solid tumor havoring NTRK fusion were treated with Larotrectinib. NTRK3 G623R mutation was deteceted in the tumor with acquired resistance. This patient was successfully treated with LOX… (full text at CIViC)

Open in CIViC

civic

v::NTRK3 Fusion AND NTRK3 G623R

Larotrectinib

Predictive

Supports Resistance

submitted

EID11541

In this phase 1/2 study 55 patients from 4 months to 76 years old with TRK-fusion positive tumors were given NTRK inhibitor larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall res… (full text at CIViC)

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

civic

Mammary Analogue Secretory Carcinoma1unmapped disease
ETV6::NTRK3 Fusion AND NTRK3 G623R	Entrectinib	Predictive	C	Supports Resistance	4	accepted	EID1874 Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followe… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic

Mammary Analogue Secretory Carcinoma1unmapped disease

ETV6::NTRK3 Fusion AND NTRK3 G623R

Entrectinib

Predictive

Supports Resistance

accepted

EID1874

Case report of a patient with mammary analogue secretory carcinoma (MASC) harboring an etv6-ntrk3 fusion. The patient was treated with entrectinib and exhibited a partial response for 7 months followe… (full text at CIViC)

PMID 26884591 · Drilon et al., 2016 · Open in CIViC

civic

Evidence by cancer (7 items)

Clinical significance (0)